dc.contributor.author | Şeber, Erdoğan Selçuk | |
dc.contributor.author | Gönültaş, Aylin | |
dc.contributor.author | Öztürk, Özlem | |
dc.contributor.author | Yetişyiğit, Tarkan | |
dc.date.accessioned | 2022-05-11T14:40:55Z | |
dc.date.available | 2022-05-11T14:40:55Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 1178-6930 | |
dc.identifier.uri | https://doi.org/10.2147/OTT.S96227 | |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/8974 | |
dc.description.abstract | Recurrent squamous cell carcinoma of the skin is a rare but difficult to treat condition. Frequently, the disease presents itself in elderly patients with poor performance status and bearing many comorbidities, thus the decision to administer systemic chemotherapy becomes difficult to make. In addition, current chemotherapeutic protocols response rates are far from satisfactory. Recently cetuximab, a chimeric antibody against epidermal growth factor receptor, is increasingly being reported as an alternative treatment. We therefore report this case of a recurrent squamous cell carcinoma of the skin in an elderly woman with poor performance status and who had an excellent clinical response to single agent cetuximab therapy with complete resolution of the disease and minimal toxicity during the course of the treatment to provide evidence for future prospective clinical trials. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Dove Medical Press Ltd | en_US |
dc.identifier.doi | 10.2147/OTT.S96227 | |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | cetuximab | en_US |
dc.subject | EGFR inhibiton | en_US |
dc.subject | squamous cell carcinoma of the skin | en_US |
dc.subject | Case Series | en_US |
dc.subject | Phase-Ii | en_US |
dc.subject | Cancer | en_US |
dc.subject | Egfr | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Cisplatin | en_US |
dc.subject | Neck | en_US |
dc.subject | Acid | en_US |
dc.subject | Head | en_US |
dc.title | Recurrent squamous cell carcinoma of the skin treated successfully with single agent cetuximab therapy | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Oncotargets and Therapy | en_US |
dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-9081-2405 | |
dc.authorid | 0000-0001-9081-2405 | |
dc.identifier.volume | 9 | en_US |
dc.identifier.startpage | 945 | en_US |
dc.identifier.endpage | 948 | en_US |
dc.institutionauthor | Şeber, Erdoğan Selçuk | |
dc.institutionauthor | Yetişyiğit, Tarkan | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 6701472672 | |
dc.authorscopusid | 56182776400 | |
dc.authorscopusid | 57225369637 | |
dc.authorscopusid | 8666331800 | |
dc.authorwosid | seber, selcuk/T-9539-2019 | |
dc.authorwosid | seber, selcuk e/H-3327-2017 | |
dc.identifier.wos | WOS:000370980200001 | en_US |
dc.identifier.scopus | 2-s2.0-84959356686 | en_US |
dc.identifier.pmid | 26955287 | en_US |